Aethlon Medical (NASDAQ:AEMD) Share Price Crosses Above 200 Day Moving Average – What’s Next?

Aethlon Medical, Inc. (NASDAQ:AEMD)’s stock price passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $2.63 and traded as high as $2.77. Aethlon Medical shares last traded at $2.21, with a volume of 875,634 shares changing hands.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Aethlon Medical in a report on Monday, April 20th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Reduce”.

Aethlon Medical Stock Performance

The stock has a market cap of $3.47 million, a P/E ratio of -0.15 and a beta of 1.50. The firm’s 50 day moving average is $2.24 and its 200 day moving average is $2.63.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aethlon Medical stock. Citadel Advisors LLC acquired a new position in shares of Aethlon Medical, Inc. (NASDAQ:AEMD) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund acquired 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned approximately 36.57% of Aethlon Medical as of its most recent SEC filing. Institutional investors own 1.99% of the company’s stock.

About Aethlon Medical

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.